|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Symptomatic treatment of mild to moderate pains of muscle-skeletal origin. Complementary treatment muscular contractures in rheumatology
Hypersensitivity to the active substance or any of its excipients. The medicine is contraindicated in case of serious hepatic impairment. Do not administer in case of flaccid paralysis or muscular hypotonia. Contraindicated in children under 10 years. Paracetamol is contraindicated in individuals that suffer from renal disorders, unless recommended by the doctor
Side effects are generally infrequent but they can be important in some cases, particularly when related to paracetamol. Hepatotoxicity with high doses and prolonged treatments. Rarely, rash and changes in blood values may occur (trombocytopenia, pancytopenia, neutropenia, agranulocytosis and haemolytic anaemia). It was also described the occurrence of pancreatitis, fever, hypoglicemia and jaundice. Exceptionally it may occur gastralgias and diarrhoea.
Adalgur N may increase the toxicity of chloramphenicol. Adalgur N may potentiate the effect of anticoagulants. However, in case of treatment with oral anticoagulants, you can take Adalgur N, occasionally, as preferred analgesic. The simultaneous administration of Adalgur N with aspirin, salicylates or non-steroidal anti-inflammatory drugs is not recommended. The concomitant use of diflunisal with Adalgur N increases the risk of hepatotoxicity. The expected analgesic response of this medicine is changed by the administration of barbiturates. The effect of Adalgur N is inhibited by the administration of cholestipol, cholestiramine and estrogens. Isoniazide reinforces the hepatotoxic capacity of Adalgur N. The following laboratory values may be increased: (plasmatic transaminases, alkaline phosphatase, ammoniac, creatinine, lactatedehydrogenase and urea. Adalgur N may cause interferences in the determination of glucose and uric acid in the blood and metadrenaline ad uric acid in the urine.
Do not exceed the maximum dose recommended per day. In treatments of more than 3 days, it is recommended that the patient consults a doctor. The concomitant treatment with drugs that have a potentially hepatotoxic action should be avoided. Do not associate to the consumption of alcoholic drinks. Pregnancy In studies with animals there are reports of malformations caused by Thiocolchicoside. There are no adequate studies in pregnant women. Therefore, the use of this medicine during pregnancy is not recommended, particularly, during the first three months of pregnancy, because the safety to the embryo and foetus was not established. The ingestion of this medicine during pregnancy should be monitored by the doctor, who should evaluate the risk-benefit relationship of the prescription. Lactation Adalgur N passes to human milk therefore it is not recommended in breast-feeding women. Elderly No special precaution is necessary when the product is used in geriatric patients. Patients with other pathologies In patients with hepatic and/or renal impairment, anaemia, cardiac or pulmonary problems avoid prolonged treatments. In case of prolonged administration, these patients should be clinically monitored
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Yaser Habrawi , F.R.C.S.Ed
Dr. Faisal Dibsi
Samir Moussa M.D.
Dr. Hani Najjar
Dr . Dirar Abboud
Dr. Tahsin Martini
Dr. Samer Al-Jneidy
Dr. Talal Sabouni